Lack of impact of cytotoxic T-lymphocyte antigen 4 gene exon 1 polymorphism on susceptibility to or clinical course of egyptian childhood immune thrombocytopenic purpura

Clinical and Applied Thrombosis/Hemostasis

Volumn 21, Issue 4, 2015, Pages 378-382

  Radwan, Eman Roshdy ^a   Goda, Rania L M ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

CTLA 4; CTLA 4 exon 1 49 A>G polymorphism; immune thrombocytopenic purpura

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOGLOBULIN; STEROID; CTLA4 PROTEIN, HUMAN;

ADOLESCENT; AGE; ALLELE; ARTICLE; CHILD; CHILDHOOD DISEASE; CONTROL GROUP; CONTROLLED STUDY; DISEASE COURSE; EGYPTIAN; EXON; FEMALE; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SPLENECTOMY; STEROID THERAPY; STRATIFICATION; TREATMENT RESPONSE; BIOSYNTHESIS; CLINICAL TRIAL; EGYPT; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETICS; INFANT; METABOLISM;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CTLA-4 ANTIGEN; EGYPT; EXONS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INFANT; MALE; POLYMORPHISM, GENETIC; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 84933033801     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029613502254     Document Type: Article

References (30)

1. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002 ; 346 (13). 995-1008
2. Zhou B, Zhao H, Yang RC, Han ZC. Multi-dysfunctional pathophysiology in ITP. Crit Rev Oncol Hematol. 2005 ; 54 (2). 107-116
3. Collins AV, Brodie DW, Gilbert RJ, et al. The interaction properties of costimulatory molecules revisited. Immunity. 2002 ; 17 (2). 201-210
4. Fallarino F, Fields PE, Gajewski TF. B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28. J Exp Med. 1998 ; 188 (1). 205-210
5. Oaks MK, Hallett KM. Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J Immunol. 2000 ; 164 (10). 5015-5018
6. Liu MF, Wang CR, Chen PC, Fung LL. Increased expression of soluble cytotoxic T-lymphocyte-associated antigen-4 molecule in patients with systemic lupus erythematosus. Scand J Immunol. 2003 ; 57 (6). 568-572
7. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science. 1994 ; 265 (5176). 1225-1227
8. Lenschow DJ, Ho SC, Sattar H, et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med. 1995 ; 181 (3). 1145-1155
9. Lundquist LM. Abatacept: a novel treatment for rheumatoid arthritis. Expert Opin Pharmacother. 2007 ; 8 (14). 2371-2379
10. Harbo HF, Celius EG, Vartdal F, Spurkland A. CTLA4 promoter and exon 1 dimorphisms in multiple sclerosis. Tissue Antigens. 1999 ; 53 (1). 106-110
11. Bicek A, Zaletel K, Gaberscek S, et al. 49A/G and CT60 polymorphisms of the cytotoxic T-lymphocyte-associated antigen 4 gene associated with autoimmune thyroid disease. Hum Immunol. 2009 ; 70 (10). 820-824
12. Jin P, Xiang B, Lin J, et al. Association of CTLA-4 A/G and CT60 gene polymorphism with type 1 diabetes and thyroid autoimmunity[in Chinese]. Zhonghua Yi Xue Za Zhi. 2009 ; 89 (18). 1246-1249
13. Li H, Ge J, Zhao H, et al. Association of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with idiopathic thrombocytopenic purpura in a Chinese population. Platelets. 2011 ; 22 (1). 39-44
14. Pavkovic M, Georgievski B, Cevreska L, Spiroski M, Efremov DG. CTLA-4 exon 1 polymorphism in patients with autoimmune blood disorders. Am J Hematol. 2003 ; 72 (2). 147-149
15. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010 ; 115 (2). 168-186
16. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009 ; 113 (11). 2386-2393
17. Harper K, Balzano C, Rouvier E, Mattei MG, Luciani MF, Golstein P. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J Immunol. 1991 ; 147 (3). 1037-1044
18. Vijayakrishnan L, Slavik JM, Illes Z, et al. An autoimmune disease associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity. 2004 ; 20 (5). 563-575
19. Baroja ML, Luxenberg D, Chau T, et al. The inhibitory function of CTLA-4 does not require its tyrosine phosphorylation. J Immunol. 2000 ; 164 (1). 49-55
20. Tivol EA, Borrielo F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995 ; 3 (5). 541-547
21. Colluci F, Bergman ML, Penha-Goncalves C, Cillio CM, Holmberg D. Apoptosis resistance of nonobese diabetic peripheral lymphocytes linked to the Idd5 diabetes susceptibility region. Proc Natl Acad Sci USA. 1997 ; 94 (16). 8670-8674
22. Marron MP, Raffel LJ, Garchon HJ, et al. Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA-4 polymorphisms in multiple ethnic groups. Hum Mol Genet. 1997 ; 6 (8). 1275-1282
23. Donner H, Braun J, Seidl C, et al. Codon 17 polymorphism of the cytotoxic T lymphocyte antigen 4 gene in Hashimoto's thyroiditis and Addison's disease. J Clin Endocrinol Metab. 1997 ; 82 (12). 4130-4132
24. Seidl C, Donner H, Fisher B, et al. CTLA-4 codon 17 dimorphism in patients with rheumatoid arthritis. Tissue Antigens. 1998 ; 51 (1). 62-66
25. Ligers A, Xu C, Saarinen S, Hillert J, Olerup O. The CTLA-4 gene is associated with multiple sclerosis. J Neuroimmunol. 1999 ; 97 (1-2). 182-190
26. Agarwal K, Jones DE, Daly AK, et al. CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. J Hepatol. 2000 ; 32 (4). 538-541
27. Kouki T, Sawai Y, Gardini CA, Fisfalen ME, Alegre ML, DeGroot LJ. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol. 2000 ; 165 (11). 6606-6611
28. Liu B, Zhao H, Poon MC, et al. Abnormality of CD4()CD25() regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol. 2007 ; 78 (2). 139-143
29. Peng J, Liu C, Liu D, et al. Effects of B7-blocking agent and/or CsA on induction of platelet-specific T-cell anergy in chronic autoimmune thrombocytopenic purpura. Blood. 2003 ; 101 (7). 2721-2726
30. Zhang XL, Peng J, Sun JZ, et al. Modulation of immune response with cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin- induced anergic T cells in chronic idiopathic thrombocytopenic purpura. J Thromb Haemost. 2008 ; 6 (1). 158-165